Home>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Atorvastatin Calcium

Atorvastatin Calcium Sale

(Synonyms: 阿托伐他汀钙; CI-981; Atorvastatin hemicalcium) 目录号 : GC14038

An HMG-CoA reductase inhibitor

Atorvastatin Calcium Chemical Structure

Cas No.:134523-03-8

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥337.00
现货
50mg
¥509.00
现货
500mg
¥3,420.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

102

客户使用产品发表文献 2

产品文档

Quality Control & SDS

View current batch:

实验参考方法

Cell experiment [1]:

Cell lines

Mononuclear cells and VSMC

Preparation method

The solubility of this compound in DMSO is > 57.8 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.

Reacting condition

0.1 or 1 μM

Applications

In mononuclear cells and VSMC, Atorvastatin Calcium (0.1 μM) significantly inhibited NF-κB activation induced by Ang II and TNF-α. Besides, Atorvastatin Calcium (1 μM) also down-regulated MCP-1 and IP-10 expressions induced by Ang II and by TNF-α.

Animal experiment [2]:

Animal models

Ischemic hindlimb mice

Dosage form

2 or 8 mg/kg/day; p.o.; 4 weeks

Applications

In ischemic hindlimb mice, Atorvastatin Calcium at the dose of 8 mg/kg significantly recovered blood flow. Besides, the ischemia/normal perfusion ratio in the 8 mg/kg Atorvastatin Calcium treatment group also increased. According to the analyses of the ischemic muscle tissues, Atorvastatin Calcium significantly increased the number of capillaries. Meanwhile, CXCR4 expression was up-regulated in these ischemic tissues.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Ortego M, Bustos C, Hernández-Presa MA, Tuón J, Díaz C, Hernández G, Egido J. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999 Dec;147(2):253-61.

[2]. Chiang KH, Cheng WL, Shih CM, Lin YW, Tsao NW, Kao YT, Lin CT, Wu SC, Huang CY, Lin FY. Statins, HMG-CoA Reductase Inhibitors, Improve Neovascularization by Increasing the Expression Density of CXCR4 in Endothelial Progenitor Cells. PLoS One. 2015 Aug 26;10(8):e0136405.

产品描述

Atorvastatin Calcium is a potent inhibitor of HMG-CoA reductase with IC50 value of 150 nM[1].
HMG-CoA reductase is the key enzyme of the mevalonate pathway which produces cholesterol. HMG-CoA is the rate-limiting enzyme and is important for lowering the blood cholesterol levels. HMG-CoA reductase is located in the endoplasmic reticulum and contains eight transmembrane domains. The inhibitors of HMG-CoA reductase can induce the LDL (low density lipoprotein) receptors expression in the liver. It leads to increase the catabolism levels of plasma LDL and lower the concentration of plasma cholesterol which is an important determinant of atherosclerosis. HMG-CoA reductase plays an important role in cholesterol synthesis. HMG-CoA is the ony target for cholesterol-lowering drugs. HMG-CoA reductase is also an important enzyme for development. The activity of HMG-CoA reductase is related to germ cell migration defects. Inhibition of its activity can leadto intracerebral hemorrhage[1].
Atorvastatin is an HMG-CoA reductase inhibitor with IC50 value of 154 nM. It is effective in treating certain dyslipidemias and hypercholesterolemia[1]. Atorvastatin treatment at 40 mg decreases total cholesterol of 40% after 40 days.[1] It also be used to treat coronary or stroke patients with normal cholesterol levels.[2] Atorvastatin also decreases low density lipoprotein apheresis in patients by inducing LDL-receptors expression.
It is metabolized to several metabolites which are important for the effect of the therapeutic actions by CYP3A4 (cytochrome P450 3A4).[3]
References:
[1].    van Dam M, Zwart M, de Beer F, Smelt AH, Prins MH, Trip MD, Havekes LM, Lansberg PJ, Kastelein JJ: Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia. Heart 2002, 88(3):234-238.
[2].    Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT et al: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361(9364):1149-1158.
[3].    Lennernas H: Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003, 42(13):1141-1160.

Chemical Properties

Cas No. 134523-03-8 SDF
别名 阿托伐他汀钙; CI-981; Atorvastatin hemicalcium
化学名 calcium;(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate
Canonical SMILES CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4.CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)[O-])O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4.[Ca+2]
分子式 C33H34Ca0.5FN2O5 分子量 577.67
溶解度 DMSO : ≥ 50 mg/mL (86.55 mM); H2O : < 0.1 mg/mL (insoluble) 储存条件 Store at 4°C, sealed storage, away from moisture
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.7311 mL 8.6555 mL 17.3109 mL
5 mM 0.3462 mL 1.7311 mL 3.4622 mL
10 mM 0.1731 mL 0.8655 mL 1.7311 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置